Skip to content
Peptigraph home

Wegovy vs Ozempic: What the Research Shows

Wegovy and Ozempic side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Brand of Semaglutide (GLP-1 agonist)FDA approved (Ozempic, Wegovy, Rybelsus)WegovyNovo Nordisk's semaglutide brand for weight management; the label covers weight reduction and long-term maintenance in adults and patients aged 12 years and older with obesity.[10]GLP-1 & metabolic
Brand of Semaglutide (GLP-1 agonist)FDA approved (Ozempic, Wegovy, Rybelsus)OzempicNovo Nordisk's injectable semaglutide brand, FDA-labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[5]GLP-1 & metabolic
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Wegovy if…

  • you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[10]
  • you want the label that includes liver disease: Wegovy has an accelerated-approval indication for MASH with moderate to advanced liver fibrosis in adults[10]
  • you want the higher-dose weight product: Wegovy's maintenance dosage in adults is 1.7 mg or 2.4 mg (recommended) injected once weekly[10]

Consider Ozempic if…

  • you want the diabetes-labelled product: Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes[5]
  • you want the label with a kidney indication: Ozempic is indicated to reduce sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease[5]
  • you want the diabetes dosing range: Ozempic's maximum recommended dosage is 2 mg once weekly[5]

What they have in common

  • Wegovy is also semaglutide: the label title reads WEGOVY (semaglutide) injection[10]
  • Ozempic is semaglutide: the label title reads OZEMPIC (semaglutide) injection[5]
Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing all 11 fields. Highlighted rows differ.

FieldWegovyOzempic
ClassBrand of Semaglutide (GLP-1 agonist)Brand of Semaglutide (GLP-1 agonist)
Also calledBrand name of SemaglutideBrand name of Semaglutide
CategoryGLP-1 & metabolicGLP-1 & metabolic
FDA statusFDA approved (Ozempic, Wegovy, Rybelsus)FDA approved (Ozempic, Wegovy, Rybelsus)
PCAC vote, Jul 2026Not on the Jul 2026 agendaNot on the Jul 2026 agenda
WADANot on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Half-lifeapproximately 1 weeksubcutaneous · FDA label (Ozempic)approximately 1 weeksubcutaneous · FDA label (Ozempic)
Evidence strengthHuman RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758
Human studies we summarised23 human (19 randomized or controlled) of 27 summarised23 human (19 randomized or controlled) of 27 summarised
Typical study doses
Named in FDA warning letters, 2026Yes (24 Aug 2026; 31 Mar 2026)Yes (24 Aug 2026; 31 Mar 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

What is the difference between Wegovy and Ozempic?

Ozempic's label opens with glycemic control: it is indicated alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes.[5]

Wegovy's label is built around weight: it is indicated to reduce excess body weight and maintain the reduction long term in adults and pediatric patients aged 12 years and older with obesity, among other uses.[10]

STEP 2 is the closest thing to a Wegovy-versus-Ozempic comparison. It randomised adults with overweight or obesity and type 2 diabetes to semaglutide 2.4 mg, semaglutide 1.0 mg or placebo for 68 weeks.[11]

In STEP 2, gastrointestinal adverse events were reported by 63.5% on 2.4 mg, 57.5% on 1.0 mg and 34.3% on placebo.[11]

Ozempic's cardiovascular evidence is SUSTAIN-6 in type 2 diabetes at high cardiovascular risk, where the primary outcome occurred in 6.6% on semaglutide and 8.9% on placebo.[12]

The same SUSTAIN-6 abstract reports significantly higher rates of retinopathy complications with semaglutide (hazard ratio 1.76).[12]

Dose ladders and devices on each label

Ozempic's label starts at 0.25 mg once weekly for 4 weeks and then moves to 0.5 mg.[5]

The Ozempic label's next step is 1 mg weekly, after at least 4 weeks on the 0.5 mg dose, when more glycemic control is needed.[5]

Ozempic's label allows a further step to 2 mg once weekly, but only after at least 4 weeks at 1 mg and only when more glycemic control is needed.[5]

For Wegovy, the label says patients tolerating 2.4 mg for at least 4 weeks may be stepped to a maximum of 7.2 mg weekly where more weight reduction is clinically indicated.[10]

The Ozempic label lists storage for single-patient-use pens that hold multiple weekly doses, and separately for single-dose prefilled syringes.[5]

Wegovy is no longer injection-only: its label now covers both an injection and tablets, with the tablets also indicated to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.[10]

Shared warnings that apply to both

Ozempic is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.[5]

The Wegovy label says not to combine it with other semaglutide products or any other GLP-1 receptor agonist, so using both brands together is not recommended.[10]

Common questions

Is Wegovy the same as Ozempic?

They share the active ingredient but are separate products with separate labels. Ozempic is labelled as a diabetes medicine, to improve glycemic control in adults with type 2 diabetes, and Wegovy's weight-reduction label is quoted in the section above.[5]

Is Wegovy stronger than Ozempic?

Both are semaglutide. In STEP 2, gastrointestinal adverse events were reported more often on 2.4 mg than on 1.0 mg.[11]

Can I take Ozempic and Wegovy together?

No. The Wegovy label says concomitant use with other semaglutide-containing products is not recommended.[10]

Which one lowers cardiovascular risk?

Wegovy tablets are labelled to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.[10]

Does Ozempic work for weight loss like Wegovy?

STEP 2 compared semaglutide 2.4 mg with 1.0 mg, the dose approved for diabetes treatment, and with placebo, for weight management in adults with overweight or obesity and type 2 diabetes.[11]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  7. 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  8. 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  9. 9PubMed search: (Ozempic[tiab]) AND (Wegovy[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  11. 11Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet (London, England) · 2021PMID 33667417Accessed 2 Oct 2026
  12. 12Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026

Found an error? Report a correction.